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Naltrexone, an antagonist of 𝜇-opioid receptors, is clinically used as adjuvant therapy of alcohol dishabituation. The aim of
the present work was to test the effect of 1mg/kg body weight of naltrexone to revert oxidative stress-related biochemical
alterations, in the hippocampus and serum of chronic alcoholic adult rats. Malondialdehyde concentration was increased and
glutathione peroxidase activity was decreased in hippocampus and serum of alcohol-treated rats. Naltrexone treatment restored
these alterations.The in vitro antioxidant ability of Ntx could not justify these effects considering the doses used.Thus this apparent
protective effect of Ntx can only be attributed to its pharmacological effects, as herein discussed.
1. Introduction
One of the goals of drug therapy for alcoholism is to avoid
or reduce alcohol consumption and relapse. In this sense,
opioid antagonists have been used for alcoholism treatment
[1]. The use of these substances is based on their property
to block opioid receptors and thereby reduce the reinforcing
properties of alcohol and opioids. Naltrexone (Ntx) is the
opioid antagonist most widely used for alcoholism because
of its safety and effectiveness in reducing alcohol intake and
craving and preventing relapse [2].
It has been proposed that endogenous opioids may mod-
ulate oxidative stress and therefore affect cell proliferation
and survival [3]. In fact, several reports suggest that Ntx
shows antiinflammatory and immunomodulatory proper-
ties [4]. Regarding oxidative stress and glutathione (GSH)
metabolism, Ntx is able to normalize hepatic GSH and lipid
peroxidation (LPO) levels while decreasing the number of
apoptotic cells in a rat model of chronic cholestasis [3].
Free radicals may directly or indirectly affect several
cellular and physiological mechanisms. They may lead to
alterations in vital macromolecules of living cells, including
DNA or membrane lipids. It has been shown that chronic
alcohol consumption leads to an increase of lipid peroxida-
tion products and a decrease of antioxidant factors such as
GSH and related enzymes in the liver [5], brain [6], retina [7],
and optic nerve [8].
The lipid content of the cellular membrane can be
attacked by ROS, and thus LPO represents a typical marker
of ROS action over lipidic membranes [9]. Central nervous
system (CNS) is highly sensitive to oxidative stress because
of its high oxygen consumption and lipid content, specially
polyunsaturated fatty acids but with low antioxidant defense
activity [10].
It has been previously reported that acute and chronic
ethanol administration induces oxidative stress, producing
LPO as well as modifying antioxidant enzyme activities in rat
hippocampus and blood [11–13]. This work reports a novel
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finding on the “antioxidant-like” effects of Ntx after ethanol
exposure.
2. Methods
2.1. Experimental Design. Thirty-two male Sprague-Dawley
(SD) rats weighing 306.58 ± 2.08 grwere housed in individual
cages with a 7 a.m. to 7 p.m. dark-light cycle, with controlled
temperature and humidity. All animal manipulations were
done according to international regulations of the European
Parliament and Council (2003/65/CE) and were approved by
the animal care and use committee of theUniversity Cardenal
Herrera. Rats were randomly divided into two groups (𝑛 =
16 each) receiving either control or alcohol liquid diet [14].
Ethanol liquid diet was administered ad libitum along the
duration of the treatment (6 weeks), and control animals
received the same volume of the corresponding pair on the
following day (pair-fed control). At the end of the 4th week
of ethanol administration, ethanol and control groups were
randomly assigned into two subgroups each (𝑛 = 8 as each
group), receiving daily either Ntx (1mg/Kg/i.p.) or saline
(same volume Ntx i.p.), keeping the same ethanol or control
liquid diet for two additional weeks.
Liquid ethanol and control diets were purchased from
Test Diet (London, UK) and prepared in liquid form with
either ethanol plus water (resulting in a 6.4% v/v ethanol con-
centration) or water alone. These diets have been developed
to supply isocaloric intake in both alcoholic and nonalcoholic
conditions, by supplementing the latter with dextrinatedmal-
tose accordingly (ethanol-derived calories at 6.4% ethanol
concentration provide 350 kcal/L).
Body weight was initially and finally recorded, and
ethanol blood level was randomly measured along the last 3
weeks of treatment by means of a standardized colorimetric
assay kit (BIOLABO, Maizy, France). Blood samples were
obtained from the tail.
All animals were sacrificed at the end of the exper-
iment by overdose of sodium pentobarbital, then brains
were rapidly extracted, and both hippocampi were dissected
and homogenized in 0.2M potassium phosphate buffer,
pH 7.0. These homogenates were used to assay glutathione
peroxidase (GPx) activity and protein and malondialdehyde
(MDA) concentrations. Samples were kept frozen (−80∘C)
until biochemical assays were performed.
The blood samples were allowed to clot at room tempera-
ture and were centrifuged at 3,000 g for 10min to separate the
serum, which was stored at −20∘C for later analysis.
2.2. Biochemical Assays: Oxidative Stress Markers and Protein
Determination. Protein content was measured by means of
the Lowry method [15]. Glutathione peroxidase activity,
which catalyzes the oxidation by H
2
O
2
of GSH to its disulfide
(GSSG), was assayed spectrophotometrically as reported by
Lawrence et al. [16] towards hydrogen peroxide, by monitor-
ing the oxidation of NADPH at 340 nm.The reactionmixture
consisted of 240mU/mL of glutathione disulfide reductase,
1mMGSH, 0.15mM NADPH in 0.1M potassium phosphate
buffer, pH 7.0, containing 1mMEDTA and 1mM sodium
azide; a 50 𝜇L sample was added to this mixture and allowed
to equilibrate at 37∘C for 3min. Reaction was started by the
addition of hydrogen peroxide to adjust the final volume of
the assay mixture to 1mL.
The concentration of malondialdehyde (MDA), a lipid
peroxidation product, was measured by liquid chromatog-
raphy as previously described [17]. Briefly, 0.1mL of sample
and 0.75mL of working solution (thiobarbituric acid 0.37%
and perchloric acid 6.4%, 2 : 1 v/v) were mixed and heated
to 95∘C for 1 h. After cooling (10min in an ice water bath),
the flocculent precipitate was removed by centrifugation
at 12,000 rpm for 10min. The supernatant (0.2mL) was
neutralised to pH 6-7 and filtered with a syringe filter prior
to injection on a Cromasil C18 5 lm column (150 9 4.6mm).
The mobile phase consisted of 50mM phosphate buffer
(pH 6.0): methanol (58 : 42, v/v). Isocratic separation was
performedwith 1.0mL/min flow (HPLC System,Waters) and
detection at 532 nm (UV/VIS HPLC-Detector 2475, Waters).
Calibration curves were run daily.
2.3. Total Antioxidant Capacity. Total antioxidant capacity of
the naltrexone solutions was determined with the Antiox-
idant Assay Kit (Cayman Chemical Company). The assay
was performed according to manufacturer’s instructions.
Absorbance was measured at 405 nm using a plate reader
(VICTOR Perkin Elmer 2030).
2.4. Statistical Analysis. The results are presented as mean
values ± SE. Statistical significance was assessed by Student’s
t-test (when comparing two groups) or when necessary by
ANOVA followed by the least significant difference (LSD)
test (when comparing more than two groups). The level of
significance was set at 𝑃 < 0.05.
3. Results
The animals mean initial weight was 284 ± 26 g in control
group, 299 ± 7 g in ethanol group, 277 ± 36 g in control plus
naltrexone group, and 302 ± 6 g in ethanol plus naltrexone
group. While at the time of sacrifice it was 398 ± 12 g in
control group, 384 ± 77 g in ethanol group, 394 ± 19 g in
control plus naltrexone group, and 383 ± 7 g in ethanol
plus naltrexone group. There were no statistically significant
differences in weight variation between groups in any phase
of the experiment (𝑃 > 0.05).
Blood ethanol concentrations of alcoholic rats ranged
from 8.6 to 20.2mmol/L, which were similar to previous
studies with this model and are clinically relevant [18].
The liquid diet volume consumed by rats receiving
ethanol was 80 ± 15mL/d or 78 ± 18mL/d (mean ±
SD) in control animals. Animals receiving ethanol plus Ntx
consumed 78 ± 12mL/d and the control + Ntx group con-
sumed 76 ± 18mL/d. No statistically significant differences
were found among groups in terms of liquid diet volume
consumption.
3.1. Hippocampal Oxidative Stress Markers and Naltrexone.
Six weeks of chronic ethanol consumption produced a sta-
tistically significantly increase of hippocampal MDA levels
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Figure 1: (a) MDA concentration in the hippocampus of animals
from control (C), ethanol (E), control plus naltrexone (C + Ntx),
and ethanol plus naltrexone (E + Ntx) groups. ∗𝑃 < 0.05 versus all
groups. (b) Gpx activity in the hippocampus of animals from control
(C), ethanol (E), control plus naltrexone (C+Ntx), and ethanol plus
naltrexone (E +Ntx) groups. ∗𝑃 < 0.05 versus C and C + Ntx.
(Figure 1(a)). Ntx was able to reverse this hippocampal
MDA increase. Ethanol treatment produced a statistically
significant decrease of hippocampal GPx activity compared
to that in control group (Figure 1(b)), whereas GPx activity in
theNtx-treated group could not recover completely to control
values but showed a clear tendency.
3.2. Effects of Naltrexone on Systemic Oxidative StressMarkers.
Serum MDA level was statistically significantly increased
only in the ethanol-treated group (Figure 2(a)), indicating
that Ntx treatment restores MDA serum levels to control
values.
A statistically significant decrease on serum GPx activity
was observed in the ethanol-treated rats, and the administra-
tion of Ntx, on the last two weeks of ethanol intake, recovered
serum Gpx activity (Figure 2(b)).
3.3. Antioxidant Capacity of Naltrexone. In order to test
whether these effects of Ntx could be attributed to direct
antioxidant properties of Ntx, antioxidant capacity was
assayed to test this possibility. Figure 3 shows the linear
correlation (𝑟 = 0.985;𝑃 < 0.001) betweenNtx concentration
and antioxidant capacity.
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Figure 2: (a) MDA concentration in serum of animals from control
(C), ethanol (E), control plus naltrexone (C+Ntx), and ethanol plus
naltrexone (E + Ntx) groups. ∗𝑃 < 0.05 versus all groups. (b) Gpx
activity in serum of animals from control (C), ethanol (E), control
plus naltrexone (C + Ntx), and ethanol plus naltrexone (E + Ntx),
groups. ∗𝑃 < 0.05 versus all groups.
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Figure 3: In vitro test of the antioxidant capacity of different
concentrations of Ntx solution (𝑟 = 0.985; 𝑃 < 0.001). The best
fit curve corresponds to 𝑦 = 0.582𝑥 + 0.0242.
4. Discussion
Present data confirmed that chronic ethanol consumption
causes LPO and therefore increases MDA levels, while it
decreases GPx activity (Figures 1 and 2). This is consistent
with previous findings describing that chronically adminis-
tered ethanol induces oxidative stress in rat hippocampus and
retina [7, 13].
Actually, different mechanisms of action dealing with
oxidative stress have been proposed for Ntx. Several studies
suggest that endogenous opioids modulate oxidative stress in
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different tissues affecting cell survival and proliferation [3].
Pretreatment with Ntx significantly reduced the circulatory
failure and liver dysfunction in a rat model of induced
sepsis by lipopolysaccharide (LPS). These effects are associ-
ated with reduced TNF-𝛼 levels and decreased superoxide
anion formation, considering that Ntx was administered
before LPS treatment [4]. Kiani and coworkers showed that
Ntx decreased liver injury in rats and mice with acute
biliary obstruction. Although the mechanisms by which
Ntx ameliorates liver injury remain unknown, these authors
suggested the prevention of hepatic GSH decrease by opioid
receptors blockade as a plausiblemechanism of action forNtx
[19], though other nonopioid effect(s) of Ntx could also be
involved in their aswell as our results. Unlike previous reports
[4, 19], one differential point of the present work is that Ntx
was administered after 4 weeks of ethanol consumption and
not before ethanol treatment in a more preventive model.
As reported herein, Ntx normalized MDA increased levels
in both hippocampus and serum. However, Ntx recovered
enzymatic Gpx activity to control values in serum and almost
in hippocampal samples.
Although it is demonstrated that Ntx has by itself
antioxidant capacity, this antioxidant effect is significant at
concentrations in the mM range, whereas the theoretical
concentration order optimally reached in plasma could be
calculated around the 𝜇M one. So it seems improbable
that the observed effects on hippocampus and serum could
be attributed to direct Ntx effects. Therefore, an opioid-
mediated signalling mechanism might be responsible for the
observed effects of Ntx, rather than a direct molecular effect,
considering the Ntx doses used.
Chronic ethanol consumption modulates the expression
of nitric oxide synthase (NOS), modulating NO production
in several brain areas [20, 21]. The reduction of ethanol-
induced MDA levels by Ntx could be explained by the
NOS activity reduction that could result in NO decay and
finally less peroxynitrite generation [22, 23]. Although little
is known about the mechanisms of action by which Ntx
works against alcoholism, present results provide evidence
of additional benefits of Ntx in improving some ethanol-
induced oxidativemisbalance in rat serum and hippocampus.
5. Conclusion
Naltrexone at the dose used is able to reverse oxidative
stressmisbalance induced by chronic ethanol treatment in rat
hippocampus and serum. More studies must be addressed to
resolve the opened question related to opioid receptors and
the antioxidant effect of Ntx.
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